地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18995651644
传真：13212737804
邮箱：sales@amyjet.com
<艾美捷科技代理Separopore品牌全系列产品
Separopore是美国生物技术公司bioWORLD旗下的核心色谱品牌，Separopore专攻多孔琼脂糖微球色谱介质，主打 "高分辨率分离纯化" 技术，覆盖亲和色谱、离子交换、分子筛等应用场景。产品广泛应用于单克隆抗体/重组蛋白纯化、病毒载体（AAV, 慢病毒）捕获，疫苗抗原精制以及核酸/酶工程等领域。
▍Separopore产品线
| 类型 | 应用场景 | 代表产品 |
| 亲和色谱介质 | 抗体/融合蛋白纯化 | Separopore® Protein A/G |
| 金属螯合介质 | 组氨酸标签蛋白捕获 | Separopore® Ni-NTA |
| 离子交换介质 | 核酸/酶纯化 | Q/S SP/CM 系列 |
| 疏水层析介质 | 膜蛋白/病毒纯化 | Phenyl/Octyl 系列 |
| 分子筛介质 | 脱盐/缓冲液置换 | Separopore® SEC Beads |
Separopore的材料特征：
①基质成分：交联 4% 或 6% 琼脂糖（agarose），形成刚性多孔珠状结构
②物理优势：高孔隙率 & 均一粒径（45-165 μm 可选）；耐压性强（可承受 >0.3 MPa 操作压力）；低非特异性吸附
③表面修饰：可定制化偶联 Protein A/G、镍离子、抗体、凝集素 等配体
▍Separopore部分产品列表
| 品名 | 规格 | 货号 |
| AMP Separopore® 4B-CL | 1 g；3 g | 20181079 |
| Anti-DYKDDDDK (FLAG) Red Separopore® 4B Microbeads viewIP™ | 1 mL | 20181114 |
| Goat Anti-Human IgG Separopore® 4B-CL | 5 mL | 20181134 |
| L-Lysine Separopore® 4B-CL | 5 mL；10 mL；25 mL | 20181070 |
| L-Methionine Separopore® 6B-CL | 10 mL；25 mL | 20181160 |
| L-Phenylalanine Separopore® 4B-CL | 5 mL；10 mL；25 mL | 20181071 |
| L-Proline Separopore® 6B-CL | 10 mL；25 mL | 20181161 |
| L-Serine Separopore® 6B-CL | 10 mL；25 mL | 20181162 |
| L-Threonine Separopore® 6B-CL | 10 mL；25 mL | 20181163 |
| L-Valine Separopore® 6B-CL | 10 mL；25 mL | 20181164 |
| Lens culinaris Lectin (LCA/LCH) - Separopore® 4B OnePASS™ Column | 3.25 mL；8 mL | 30330004-1 |
| Lycopersicon esculentum Lectin (LEL/LEA) - Separopore® 4B OnePASS™ Column | 3.25 mL；6 mL | 30330005-1 |
| Maackia amurensis Lectin (MAA/MAL I) - Separopore® 4B OnePASS™ Column | 3 mL | 20120088-1 |
| Maclura pomifera Lectin (MPL/MPA) - Separopore® 4B OnePASS™ Column | 3 mL | 21511124-1 |
| MagneZoom™ (Paramagnetic Beads) Control | 1 mL；2 mL | 20162011-2 |
| Maltose Separopore® 4B (Epoxy-Coupled) | 10 mL；25 mL；50 mL；100 mL | 20181175 |
| Mannose Separopore® 4B-CL (Divinyl Sulfone-Coupled) | 10 mL；25 mL；50 mL；100 mL | 20181019 |
| Mannose Separopore® 4B-CL (Epoxy-Coupled) | 10 mL；25 mL；50 mL；100 mL | 20111005 |
| Melibiose Separopore® 4B (Divinyl Sulfone-Coupled) | 10 mL；25 mL | 20181178 |
| Melibiose Separopore® 4B (Epoxy-Coupled) | 10 mL；25 mL | 20181148-1 |
| N-Acetyl-D-Galactosamine Separopore® 4B-CL | 2 mL；5 mL；10 mL | 20181021 |
| N-Acetyl-D-Glucosamine (GlcNAc) Separopore® 4B-CL | 2 mL；5 mL；10 mL | 20181022 |
| NAADP Separopore® 4B-CL | 2 g | 20181122 |
| NAADP Separopore® 4B-CL (Carboxyl-Linked) | 2 g | 20181123 |
| Nickel Red Separopore® 4B Microbeads viewIP™ | 1 mL | 20181117 |
| Phaseolus vulgaris Lectin (PHA-E) - Separopore® 4B OnePASS™ Column | 3.25 mL；6 mL | 30330023-1 |
| Phaseolus vulgaris Lectin (PHA-E+L) - Separopore® 4B OnePASS™ Column | 3.25 mL；6 mL | 30330027-1 |
| Phaseolus vulgaris Lectin (PHA-L) - Separopore® 4B OnePASS™ Column | 3.25 mL；6 mL | 30330036-1 |
| Pisum sativum Lectin (PSA/PSL) - Separopore® 4B OnePASS™ Column | 3 mL | 21511137-1 |
艾美捷科技特约代理Bio X Cell抗体产品。
Bio X Cell位于美国Lebanon, New Hampshire，专注于为生物医药领域制造从毫克到克级的高品质单克隆抗体。
Bio X Cell specializes in manufacturing high quality, bulk quantity (milligram to gram) monoclonal antibodies for biomedical research. All our products are manufactured in the United States in our Lebanon, New Hampshire facility. At Bio X Cell we strive to provide scientists with ultra-pure antibodies targeting both well-characterized and novel antigens in the large quantities required for in vivo preclinical studies. We aim to facilitate the advancement of scientific discovery and innovation by providing our products at outstanding prices and backing them up with exceptional customer and technical support.
Bio X Cell的主要抗体包括：
（1）按CELL TYPE分为
T Cells
B Cells
NK Cells
Neutrophils
Monocytes & Macrophages
Dendritic Cells
（2）按AREA OF RESEARCH分为
Immunology
Innate Immunity
Cancer Biology
Immune Checkpoint Proteins
Cytokines and Chemokines
Cytokine Receptors
Cell Migration & Adhesion
Apoptosis
" data-original="http://genekam.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理Bio X Cell抗体产品"> 艾美捷科技特约代理Bio X Cell抗体产品
Kalen Biomedical为全世界范围内的心血管研究机构提供一流品质的脂蛋白（lipoprotein）。通过制定严格的生产流程和高标准的质控体系，Kalen Biomedical能够保证产品品质的持续稳定性。Kalen Biomedical的产品线包括天然的人类脂蛋白，氧化和乙酰化的低密度脂蛋白，此外还有脂蛋白探针、脂蛋白缺失血清和培养基。
Kalen Biomedical, LLC provides premium quality lipoproteins for the international cardiovascular research community. Kalen has developed stringent manufacturing procedures and Quality Control to ensure our products perform consistently.
Kalen’s lipoprotein product line includes native human lipoproteins and oxidized and acetylated Low Density Lipoproteins (LDL). Our lipoprotein probes offer the convenience of fluorescence or biotin labeled LDL. We supply lipoprotein depleted serum media supplement for specialized cell cultures (shipment to North America only).
Kalen Biomedical的主要产品包括：
Native Lipoproteins
Acetylated Lipoproteins
Oxidized Lipoproteins
Labeled Lipoproteins
Lipoprotein Depleted Sera
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
< " data-original="http://genekam.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Kalen Biomedical"> Kalen Biomedical
INDOOR Biotechnologies公司专注于室内空气品质、环境科学、过敏和哮喘相关的检测用产品和服务。
Indoor Biotechnologies was founded by Dr. Martin D. Chapman, formerly Professor of Medicine and Microbiology at the University of Virginia and a member of the UVA Asthma and Allergic Diseases Center. Dr. Chapman is a Fellow of the American Academy of Allergy, Asthma and Immunology and has served as a consultant to the U.S. National Institutes of Health, the Environmental Protection Agency, academic institutions and Fortune 500 companies..
INDOOR Biotechnologies公司的主要产品包括：
Multiplex IgE-QBA™ Kits
MARIA® Kits
ELISA Kits
Purified Allergens
Molecular Reference Standards
Antibodies
Rhinovirus Products
Allergen Standards
RhinixPRO Nasal Filters
Rapid Test and Dust Collection
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://genekam.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="INDOOR Biotechnologies"> INDOOR Biotechnologies
艾美捷科技代理ADS Biotec核酸色谱柱系列产品，用于RNA、DNA的分离和纯化。
RNASep™ 和DNASep™ 柱由均匀的烷基化无孔或大孔聚苯乙烯-二乙烯基苯（PS-DVB）共聚物微球组成，提供优异的分辨率和优异的灵敏度。
柱可以与大多数HPLC系统一起使用，以实现一致的性能和更快的纯度评估。
OligoSep™ HC Cartridge – High Capacity Oligonucleotide Separation Column
货号：NUC-99-3560
RNASep™ Semi-Prep – Ultra High Capacity RNA Purification Column
货号：RPC-99-3015
RNASep™ Semi-Prep – High Capacity RNA Purification Column
货号：RPC-99-2110
RNASep™ Prep – RNA Purification Column
货号：RNA-99-3810
OligoSep™ Prep HC Cartridge – High Capacity Oligonucleotide Purification Column
货号：NUC-99-3860
OligoSep™ Cartridge – Oligonucleotide Analysis Column
货号：NUC-99-3550
DNASep™ HT Cartridge – High Throughput DNA Separation Column
货号：DNA-99-3710
DNASep™ Cartridge – DNA Separation Column
货号：DNA-99-3510
艾美捷科技代理Antigenix免疫学研究工具
ANTIGENIX AMERICA是一家致力于生物医学研究的免疫学研究产品供应商。ANTIGENIX AMERICA团队在免疫学研究试剂的生产、销售和服务方面拥有20多年的经验；产品应用范围包括：
细胞因子研究、流式细胞术、免疫组织学、蛋白质印迹、功能研究和ELISA。物种涵盖人、小鼠、大鼠、兔、猪和犬等。
产品包括：
Super-X Plex®流式专用细胞因子试剂盒
细胞因子ELISA试剂盒和ELISA构建试剂盒
重组细胞因子和生长因子
细胞因子和生长因子抗体
CD标记物抗体，病毒蛋白，粘附标记物
ELISA辅助试剂，二抗
< " data-original="http://genekam.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Antigenix免疫学研究工具"> 艾美捷科技代理Antigenix免疫学研究工具
艾美捷科技特约代理Ellastin Products Company公司产品。Ellastin Products Company成立30余年，产品不多但是获得了许多客户的青睐，这些客户遍布于高校，研究机构，医学中心等。
Elastin Products Company, Inc. has been manufacturing quality biochemicals for 30 years. Providing research products to many pharmaceutical companies, universities, and researchers. Our quality in products have been estabilished for many years through the publishing of papers using EPC as the source. Thank you for the continued interest in our products.
ELASTIN PRODUCTS COMPANY的主要产品包括：
Polyclonal Antibody to Human Lung Tryptase IgG purified
Polyclonal Antibody to Proteinase 3-IgG purified
Polyclonal Antibody to Porcine Pancreas Elastase
Polyclonal Antibody to Human Myeloperoxidase
Monoclonal Antibody to Bovine Ligamentum Nuchae Elastin
Human Sputum Leucocyte Myeloperoxidase
Elastin Soluble
Lipase
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://genekam.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Elastin Products Company"> Elastin Products Company
Mirus Bio公司是世界上最早开发高效、低细胞毒性转染试剂的公司之一，同时也是目前该类试剂最主要的供应商之一。Mirus Bio的大部分转染试剂可以在含有血清的培养基中进行转染，省去了更换培养基的麻烦。TransIT-L1是Mirus产品的王牌，自1995年开发出来就申请了美国专利(US 5,744,335)。该项专利技术后来License给了Roche公司，以Fugene 6的品牌对外销售。TransIT-TKO & siQUEST转染试剂是常规siRNA转染试剂的王牌，与脂质体介导的转染试剂相比，该转染试剂可以高效转染siRNA，并且极大地降低了细胞的损伤程度。该试剂与siRNA混合转染细胞时，可以特异性剔除某些基因的表达，用于siRNA介导的基因沉默现象的研究。TransIT-Oligo转染试剂是即用型试剂，可以高效地将各种类型的寡聚核苷酸和寡聚脱氧核苷酸转染至受体细胞中。
此外，Mirus Bio还开发了专门针对特殊细胞的体外转染试剂，例如分别针对Jurkat，COS，3T3等细胞的转染试剂。Mirus Bio的科学家们新近开发了一种新的DNA转染试剂：TransITTM-2020 Transfection Reagent。TransITTM的性能优于FuGENETM、LipofectamineTM 2000和 LipofectamineTM 2000 CD；可在多种类型的细胞（包括难转染细胞）中实现高表达。
Mirus was founded on the principle that non-viral (i.e. plasmid DNA based) methods offer distinct advantages over viral methods of gene transfer. Our initial breakthrough in 1996 came with the development of a new type of transfection reagent that combined high efficiency delivery with low cellular toxicity: TransIT®-LT1 (Low Toxicity) Reagent remains the “gold standard” for broad-based gene delivery applications.
Mirus Bio公司主要产品：
Transfection with TransIT
Ingenio® Electroporation
Virus Production
Labeling with Label IT®
In Vivo Delivery
Accessory Products
| 品名 | 货号 |
| Human IgG1 Expression Control – 100 ug | MIR 6250 |
| Ingenio EZporator Electroporation System | MIR 51000 |
| Label IT Nucleic Acid Labeling Kit, Amine – sufficient for modifying 25 µg of nucleic acid | MIR 3925 |
| Label IT Nucleic Acid Labeling Kit, Amine – sufficient for modifying 100 µg of nucleic acid | MIR 3900 |
| TransIT-2020 Transfection Reagent – 0.4 mL | MIR 5404 |
| TransIT-2020 Transfection Reagent – 1.0 mL | MIR 5400 |
| TransIT-2020 Transfection Reagent – 10 X 1.0 mL | MIR 5406 |
| TransIT-2020 Transfection Reagent – 5 X 1.0 mL | MIR 5405 |
| TransIT-293 Transfection Reagent – 0.4 mL | MIR 2704 |
| TransIT-293 Transfection Reagent – 1.0 mL | MIR 2700 |
| TransIT-293 Transfection Reagent – 10 X 1.0 mL | MIR 2706 |
| TransIT-293 Transfection Reagent – 5 X 1.0 mL | MIR 2705 |
| TransIT-CHO Transfection Kit – 10 X 1.0 mL | MIR 2176 |
| TransIT-CHO Transfection Kit – 5 X 1.0 mL | MIR 2175 |
| TransIT-CHO Transfection Kit – 1.0 mL | MIR 2170 |
| TransIT-HeLaMONSTER Transfection Kit – 0.4 mL | MIR 2904 |
| TransIT-HeLaMONSTER Transfection Kit – 1.0 mL | MIR 2900 |
| TransIT-HeLaMONSTER Transfection Kit – 10 X 1.0 mL | MIR 2906 |
| TransIT-HeLaMONSTER Transfection Kit – 5 X 1.0 mL | MIR 2905 |
| TransIT-Insect Transfection Reagent – 0.4 mL | MIR 6104 |
| TransIT-Insect Transfection Reagent – 1.0 mL | MIR 6100 |
| TransIT-Insect Transfection Reagent – 10 X 1.0 mL | MIR 6106 |
| TransIT-Insect Transfection Reagent – 5 X 1.0 mL | MIR 6105 |
| TransIT-Jurkat Transfection Reagent – 0.4 mL | MIR 2124 |
| TransIT-Jurkat Transfection Reagent – 1.0 mL | MIR 2120 |
| TransIT-Jurkat Transfection Reagent – 10 X 1.0 mL | MIR 2126 |
| TransIT-Jurkat Transfection Reagent – 5 X 1.0 mL | MIR 2125 |
| TransIT-Keratinocyte Transfection Reagent – 0.4 mL | MIR 2804 |
| TransIT-Keratinocyte Transfection Reagent – 1.0 mL | MIR 2800 |
| TransIT-Keratinocyte Transfection Reagent – 10 X 1.0 mL | MIR 2806 |
| TransIT-Keratinocyte Transfection Reagent – 5 X 1.0 mL | MIR 2805 |
| TransIT-LT1 Transfection Reagent – 0.4 mL | MIR 2304 |
| TransIT-LT1 Transfection Reagent – 5 X 1.0 mL | MIR 2305 |
| TransIT-mRNA Transfection Kit – 0.4 mL | MIR 2225 |
| TransIT-mRNA Transfection Kit – 1.0 mL | MIR 2250 |
| TransIT-mRNA Transfection Kit – 10 X 1.0 mL | MIR 2256 |
| TransIT-mRNA Transfection Kit – 5 X 1.0 mL | MIR 2255 |
| TransIT-Oligo Transfection Reagent – 0.4 mL | MIR 2164 |
| TransIT-Oligo Transfection Reagent – 1.0 mL | MIR 2160 |
| TransIT-Oligo Transfection Reagent – 10 X 1.0 mL | MIR 2166 |
| TransIT-Oligo Transfection Reagent – 5 X 1.0 mL | MIR 2165 |
| TransIT-PRO Transfection Kit – 1.0 mL (with boost) | MIR 5700 |
| TransIT-PRO Transfection Kit – 10 mL (with boost) | MIR 5760 |
| TransIT-PRO Transfection Reagent – 1 mL (without boost) | MIR 5740 |
| TransIT-PRO Transfection Reagent – 10 mL (without boost) | MIR 5750 |
| TransIT-siQUEST Transfection Reagent – 0.4 mL | MIR 2114 |
| TransIT-siQUEST Transfection Reagent – 1.5 mL | MIR 2110 |
| TransIT-siQUEST Transfection Reagent – 10 X 1.5 mL | MIR 2116 |
| TransIT-siQUEST Transfection Reagent – 5 X 1.5 mL | MIR 2115 |
| TransIT-TKO Transfection Reagent – 0.4 mL | MIR 2154 |
| TransIT-TKO Transfection Reagent – 1.5 mL | MIR 2150 |
| TransIT-TKO Transfection Reagent – 10 X 1.5 mL | MIR 2156 |
| TransIT-TKO Transfection Reagent – 5 X 1.5 mL | MIR 2155 |
| TransIT-X2 Dynamic Delivery System – 0.3 mL | MIR 6003 |
| TransIT-X2 Dynamic Delivery System – 0.75 mL | MIR 6004 |
| TransIT-X2 Dynamic Delivery System – 1.5mL | MIR 6000 |
| TransIT-X2 Dynamic Delivery System – 10 X 1.5 mL | MIR 6006 |
| TransIT-X2 Dynamic Delivery System – 5 X 1.5 mL | MIR 6005 |
| Ingenio Electroporation Accessory – Cell Droppers (50 pk) | MIR 50125 |
| Ingenio Electroporation Solution Only – 25 rxns (6.25 mL) | MIR 50111 |
| Label IT Nucleic Acid Labeling Kit, Biotin – labels 100 µg nucleic acid | MIR 3400 |
| Label IT Plasmid Delivery Control, Cy3 – 10 µg | MIR 7904 |
| Label IT RNAi Delivery Control, Cy3 – 10 µg (0.75 nmol) | MIR 7900 |
| TransduceIT Transduction Reagent – 1 mL | MIR 6620 |
| TransIT-BrCa Reagent Transfection Reagent – 0.4 mL | MIR 5504 |
| Ingenio Electroporation Accessory – 0.4 cm Cuvettes (50 pk) | MIR 50123 |
| Ingenio Electroporation Solution Only – 50 rxns (12.5 mL) | MIR 50114 |
| Label IT Nucleic Acid Labeling Kit, Biotin – labels 25 µg nucleic acid | MIR 3425 |
| Label IT Plasmid Delivery Control, Cy3 – 100 µg | MIR 7905 |
| Label IT RNAi Delivery Control, Cy3 – 100 µg (7.5 nmol) | MIR 7901 |
| Label IT siRNA Tracker Intracellular Localization Kit, CX-Rhodamine – labels 50 µg siRNA | MIR 7214 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, CX-Rhodamine – labels 50-200 µg plasmid DNA | MIR 7022 |
| Lentivirus Packaging Mix – 34 rxn | MIR 6640 |
| TransIT-BrCa Reagent Transfection Reagent – 1.0 mL | MIR 5500 |
| TransIT-LT1 Transfection Reagent – 1.0 mL | MIR 2300 |
| Ingenio Electroporation Accessory – 0.2 cm Cuvettes (50 pk) | MIR 50121 |
| Ingenio Electroporation Solution Only – 100 rxns (25 mL) | MIR 50117 |
| Label IT Nucleic Acid Labeling Kit, CX-Rhodamine – labels 100 µg nucleic acid | MIR 3100 |
| Label IT Plasmid Delivery Control, Fluorescein – 10 µg | MIR 7906 |
| Label IT RNAi Delivery Control, Fluorescein – 10 µg (0.75 nmol) | MIR 7902 |
| Label IT siRNA Tracker Intracellular Localization Kit, Cy3 – labels 50 µg siRNA | MIR 7212 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, Cy3 – labels 50-200 µg plasmid DNA | MIR 7020 |
| Lentivirus Packaging Mix – 5 rxn | MIR 6630 |
| TransIT-BrCa Transfection Reagent – 5 x 1.0 mL | MIR 5505 |
| Ingenio Electroporation Kit, for Amaxa – 25 rxns (0.2 cm Cuvettes/Droppers) | MIR 50112 |
| Label IT Nucleic Acid Labeling Kit, CX-Rhodamine – labels 25 µg nucleic acid | MIR 3125 |
| Label IT Plasmid Delivery Control, Fluorescein – 100 µg | MIR 7907 |
| Label IT RNAi Delivery Control, Fluorescein – 100 µg (7.5 nmol) | MIR 7903 |
| Label IT siRNA Tracker Intracellular Localization Kit, Cy5 – labels 50 µg siRNA | MIR 7213 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, Cy5 – labels 50-200 µg plasmid DNA | MIR 7021 |
| TransIT Lentivirus System – 34 rxn | MIR 6655 |
| TransIT-BrCa Transfection Reagent – 10 x 1.0 mL | MIR 5506 |
| TransIT-LT1 Transfection Reagent – 10 X 1.0 mL | MIR 2306 |
| Ingenio Electroporation Kit, for Amaxa – 50 rxns (0.2 cm Cuvettes/Droppers) | MIR 50115 |
| Label IT Nucleic Acid Labeling Kit, Cy3 – labels 100 µg nucleic acid | MIR 3600 |
| Label IT siRNA Tracker Intracellular Localization Kit, Fluorescein – labels 50 µg siRNA | MIR 7216 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, Fluorescein – labels 50-200 µg plasmid DNA | MIR 7025 |
| TransIT Lentivirus System – 5 rxn | MIR 6650 |
| Ingenio Electroporation Kit, for Amaxa – 100 rxns (0.2 cm Cuvette/Droppers) | MIR 50118 |
| Label IT Nucleic Acid Labeling Kit, Cy3 – labels 25 µg nucleic acid | MIR 3625 |
| TransIT-Lenti Transfection Reagent – 10 x 1.5 mL | MIR 6606 |
| Ingenio Electroporation Kit, for other Electroporators – 25 rxns, (0.4 cm Cuvettes/Droppers) | MIR 50113 |
| Label IT Nucleic Acid Labeling Kit, Cy5 – labels 100 µg nucleic acid | MIR 3700 |
| TransIT-Lenti Transfection Reagent – 1.5 mL | MIR 6600 |
| Ingenio Electroporation Kit, for other Electroporators – 50 rxns (0.4 cm Cuvettes/Droppers) | MIR 50116 |
| Label IT Nucleic Acid Labeling Kit, Cy5 – labels 25 µg nucleic acid | MIR 3725 |
| TransIT-Lenti Transfection Reagent – 0.75 mL | MIR 6604 |
| Ingenio Electroporation Kit, for other Electroporators – 100 rxns (0.4 cm Cuvette/Droppers) | MIR 50119 |
| TransIT-Lenti Transfection Reagent – 5 x 1.5 mL | MIR 6605 |
| TransIT-Lenti Transfection Reagent – 0.3 mL | MIR 6603 |
| Label IT Nucleic Acid Labeling Kit, DNP – labels 100 µg nucleic acid | MIR 3800 |
| Label IT Nucleic Acid Labeling Kit, DNP – labels 25 µg nucleic acid | MIR 3825 |
| Label IT Nucleic Acid Labeling Kit, Fluorescein – labels 100 µg nucleic acid | MIR 3200 |
| Label IT Nucleic Acid Labeling Kit, Fluorescein – labels 25 µg nucleic acid | MIR 3225 |
| Label IT Nucleic Acid Labeling Kit, MFP488 – labels 100 µg nucleic acid | MIR 7100 |
| Label IT Nucleic Acid Labeling Kit, MFP488 – labels 25 µg nucleic acid | MIR 7125 |
| TransIT-EE Delivery Solution – 40 Injections | MIR 5340 |
| TransIT-QR Delivery Solution – 40 Injections | MIR 5240 |
| pLIVE Vector – 20 ug | MIR 5420 |
| pLIVE Vector/LacZ – 20 ug of each vector | MIR 5520 |
| pLIVE Vector/SEAP Control Vector Kit – 20 ug of each vector | MIR 5620 |
| pLIVE Vector Complete System – 20 ug of each vector | MIR 5320 |
| RevIT AAV Enhancer – 1.5 mL (for 1 L of cell culture) | MIR 8000 |
| TransIT-VirusGEN GMP Transfection Reagent – 150 mL | MIR 6845-GMP |
| VirusGEN AAV Transfection Kit – 150mL | MIR 6755 |
| VirusGEN AAV Transfection Kit, 1 Kit – for 10 L of cell culture | MIR 6745 |
| RevIT AAV Enhancer – 10 x 1.5 mL (for 10 L of cell culture) | MIR 8006 |
| RevIT AAV Enhancer – 75 mL (for 50 L of cell culture) | MIR 8080 |
| VirusGEN GMP LV Transfection Kit | MIR 6825-GMP |
| VirusGEN LV Transfection Kit | MIR 6760 |
| VirusGEN AAV Kit + RevIT for 10L Culture | MIR 8008 |
| VirusGEN GMP AAV Transfection Kit | MIR 6815-GMP |
| VirusGEN AAV Transfection Kit – 1 Kit for 1 L of cell culture | MIR 6750 |
| VirusGEN AAV Kit + RevIT for 1L Culture | MIR 8007 |
| TransIT-VirusGEN Transfection Reagent – 150 mL | MIR 6740 |
| TransIT-VirusGEN Transfection Reagent – 30 mL | MIR 6720 |
| TransIT-VirusGEN Transfection Reagent – 10 x 1.5 mL | MIR 6706 |
| TransIT-VirusGEN Transfection Reagent – 5 x 1.5 mL | MIR 6705 |
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
艾美捷科技特约代理CUSABIO公司产品。Cusabio专注于研发生产基因、蛋白、抗体、ELISA试剂盒、体外诊断原料、小分子等产品，还涉及食品安全和药物残留领域。
CUSABIO is a National High-Tech Enterprise with research, production and sales in one. After 11 years of effort, CUSABIO has become a good partner to researchers through worldwide. We are dedicated to providing 60,000+ validated antibodies, 6000+ recombinant proteins, 580+ cytokines and thousands of ELISA kits to global customers in the research fields of cancer, cell biology, immunology, neuroscience, epigenetics, etc. All kinds of our products can meet customers' different demands in various scientific research fields.
Cusabio的主要产品包括：
（1）Kit
ELISA Kit
Elisa Kit For Food Safety & Drug Residues
Hot Product
Food Safety Small Molecule Antigen
（2）Protein
Native Protein
Recombinant Protein
Active Protein
Transmembrane Protein
（3）Antibody
Polyclonal Antibodies
Secondary Antibodies
Monoclonal Antibodies
Tag/Control Antibodies
Small Molecules Antibodies
ChIP Antibodies
Antibody Pairs
Recombinant Antibodies
Custom Antibodies
（4）Molecular Biology Product
RT-PCR Primers
Clone
Tools Enzyme
Other Small Molecule Antigen
Peptide
（5）Wisherkon Food Safety Test Kits
ELISA Test Kits
Rapid Test Card/Strip
Chemical Reagents
（6）Raw Material For IVD Kit
CUSAg
" data-original="http://genekam.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Cusabio"> Cusabio
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年，提供近200种亚磷酰胺和核苷酸合成用固相交联单体，以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.
Berry & Associates的主要产品包括：
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://genekam.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：15172431432
传真：15172469628
邮箱：sales@amyjet.com
0.4213
